Insilico Doses First Patient in AI-Driven Phase 3 IPF Trial
New York, New York, September 10, 2026 Insilico Medicine has announced that the first patient has been dosed in...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
New York, New York, September 10, 2026 Insilico Medicine has announced that the first patient has been dosed in...
South San Francisco, California and Paris, France, September 9, 2026 IDEAYA Biosciences and Servier have announced that the first...
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
Basel, Switzerland, London, United Kingdom & New York – August 27, 2026 Roivant announced that the U.S. Food and...
Hong Kong, Shanghai & Florham Park, New Jersey – August 28, 2026 HUTCHMED announced that China’s National Medical Products...
